Recent reports have addressed the following issues related to prostate cancer:
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: ADT, androgen deprivation therapy, biopsy, fractures, gefitinib, hypoxia, Iressa, microenvironment, radical prostatectomy, tumor | Leave a comment »
Tomorrow (Thursday) an advisory committee to the US Food and Drug Administration (FDA) meets to decide whether to recommend approval of Amgen’s new RANK-L inhibitor, denosumab, which offers an entirely new mechanism for the reduction of the risk of fractures and other skeletal related events (SREs) caused by long term hormone therapy (both in patients with breast cancer and those with prostate cancer). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: denosumab, fractures | Leave a comment »
Two important papers presented this afternoon addressed data on the use of toremifene and denosumab on the bones of men receiving treatment with androgen deprivation therapy (ADT). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation therapy, bone mineral denisty, denosumab, fractures, toremifene | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 